Redefining Injectables.
One Layer at a Time.

27 January, 2026

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

• Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.
• Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.

Read more

10 December, 2025

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.

6 November, 2025

Nanexa publishes interim report for January-September 2025

Download attachment

27 August, 2025

Nanexa publishes interim report for January-June 2025

Download attachment